ABT-072

ABT-072 is a small molecule investigational drug developed as a direct antiviral agent for the treatment of hepatitis C virus (HCV) infection. It acts as a potent non-nucleoside inhibitor of the HCV NS5B RNA-dependent RNA polymerase, with selectivity for genotype 1a and 1b HCV replicons. The compound was designed to improve oral bioavailability and pharmacokinetic properties compared to earlier leads. In clinical studies, ABT-072 demonstrated good potency and was evaluated in combination regimens for chronic hepatitis C infection. Its mechanism involves inhibition of viral RNA synthesis by binding to an allosteric site on the NS5B polymerase, thereby blocking viral replication initiation[5][6][7].

Other names

(E)-N-(4-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide